Tejerina Miranda, SandraBlázquez-García, MarinaSerafín González-Carrato, VerónicaMontero-Calle, AnaGarranzo-Asensio, MariaReviejo García, Ángel JulioPedrero Muñoz, MaríaPingarrón Carrazón, José ManuelBarderas Manchado, RodrigoCampuzano Ruiz, Susana2025-01-102025-01-102023Sandra Tejerina-Miranda, Marina Blázquez-García, Verónica Serafín, Ana Montero-Calle, Maria Garranzo-Asensio, A. Julio Reviejo, María Pedrero, José M. Pingarrón, Rodrigo Barderas, Susana Campuzano, Electrochemical biotool for the dual determination of epithelial mucins associated to prognosis and minimal residual disease in colorectal cancer, International Journal of Biological Macromolecules, Volume 248, 2023, 125996, ISSN 0141-813010.1016/j.ijbiomac.2023.125996https://hdl.handle.net/20.500.14352/113814This work reports a dual immunoplatform for the simultaneous detection of two epithelial glycoproteins of the mucin family, mucin 1 (MUC1) and mucin 16 (MUC16), whose expression is related to adverse prognosis and minimal residual disease (MRD) in colorectal cancer (CRC). The developed immunoplatform involves functionalised magnetic microparticles (MBs), a set of specific antibody pairs (a capture antibody, cAb, and a biotinylated detector antibody b-dAb labelled with a streptavidin-horseradish peroxidase, Strep-HRP, polymer) for each target protein and amperometric detection at dual screen-printed carbon electrodes (SPdCEs) using the hydroquinone (HQ)/horseradish peroxidase (HRP)/H2O2 system. This dual immunoplatform allows, under the optimised experimental conditions, to achieve LOD values of 50 and 1.81 pg mL−1 (or mU mL−1) for MUC1 and MUC16, respectively, and adequate selectivity for the determination of the two targets in the clinic. The developed immunoplatform was employed to analyse CRC cell protein extracts (1.0 μg/determination) with different metastatic potential providing results in agreement with those obtained by blotting technologies but using affordable and applicable point-of-care instruments. This new biotool also emerges competitive in state-of-the-art electrochemical immunoplatforms seeking a compromise among simplicity, reduction of test time and analytical characteristics.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal articlehttps://doi.org/10.1016/j.ijbiomac.2023.125996open access543Electrochemical immunoplatformsMucinsColorectal cancerAggressivenesscancer cellsCiencias2301 Química Analítica